Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fara, A."'
Autor:
Fara Brasó-Maristany, Marta Guzman, Josep Tabernero, Mafalda Oliveira, Zighereda Ogbah, Judit Grueso, Maurizio Scaltriti, Mireia Parés, Aleix Prat, Oriol Casanovas, Elena Garralda, Jordi Rodon, Olga Rodriguez, Mònica Sánchez-Guixé, Cinta Hierro, Analia Azaro, Violeta Serra, Rodrigo Dienstmann, Paolo Nuciforo, Ana Vivancos, Cristina Saura, Erika Monelli, Mariona Graupera, Guillermo Villacampa, José Antonio Jiménez, Cristina Viaplana
Publikováno v:
Clinical Cancer Research. 28:137-149
Purpose:FGFR1 amplification (FGFR1amp) is recurrent in metastatic breast cancer (MBC) and is associated with resistance to endocrine therapy and CDK4/6 inhibitors (CDK4/6is). Multi-tyrosine kinase inhibitors (MTKIs) and selective pan-FGFR inhibitors
Autor:
Zachary J. Cartun, Mike Thomas, Silvia Buonamici, Donna Neuberg, Lili Wang, Jing Deng, Fara Faye Regis, Anthony Letai, Kaitlyn Baranowski, Ruben D. Carrasco, Catherine J. Wu, Elisa Ten Hacken
Publikováno v:
Clinical Cancer Research. 23:29-29
The spliceosome component SF3B1 is among the most frequently mutated genes in CLL (Landau et al. Nature 2015), and its mutations are associated with transcriptomic changes in numerous pathways involved in the regulation of CLL-cell survival (Wang et
Autor:
Yi-Hsuan Tsai, Joel S. Parker, Laia Paré, Vanessa Rodrik-Outmezguine, Barbara Adamo, Tomás Pascual, Fara Brasó-Maristany, Stephen R. D. Johnston, Aleix Prat, Eva Ciruelos, Maria Vidal, Patricia Galván, Jan C. Brase
Publikováno v:
Clinical Cancer Research
Purpose: Predicting prognosis in HR+/HER2− metastatic breast cancer (MBC) might be clinically useful; however, no validated prognostic biomarkers exist in this setting to date. Patients and Methods: In phase III, EGF30008 trial, 484 patients with H